



ASX Release

29 May 2026

UPDATE - Acrux licenses Lenzetto® for the Australian market for AUD 5.4 million

Melbourne, Australia – 28 May 2026: Further to our release of 28 May 2026 where we announced the licensing of Lenzetto® for the Australian market for milestones up to AUD 5.4 million, the following additional details are provided.

The first payment Acrux will receive will be an upfront signing milestone which becomes due 14 days following execution of the amendment.

The second regulatory milestone becomes receivable when the marketing authorisation from the Therapeutic Goods Authority (TGA) in the Australian territory is achieved. Gedeon Richter Plc will be responsible for registration of Lenzetto® in Australia.

The third and final commercial milestone is receivable at the earlier date following either of the following triggers:

1. achievement of a cumulative sales target
2. the second anniversary following product launch.

To view the original announcement and an accompanying video from Acrux's CEO and Managing Director, John Warmbrunn, visit Acrux's Investor Centre by clicking [here](#)

[Click here to sign up to our InvestorHub](#) and keep up to date with Acrux's news and the latest developments.

This announcement has been authorised for release to the ASX by the Chair of Acrux.

For more information, please contact:

John Warmbrunn

CEO & Managing Director

E: john.warmbrunn@acrux.com.au

P: + 61 3 8379 0100

Julia Maguire

Media Relations

The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 2 7257 7338

About Acrux

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

For further information on Acrux, visit: www.acrux.com.au